Patents by Inventor Fumiaki Yokokawa
Fumiaki Yokokawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240352030Abstract: A compound of Formula (1) is provided that has been shown to be useful for treating a disease caused by a viral infection: wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.Type: ApplicationFiled: May 7, 2024Publication date: October 24, 2024Inventors: Cyrille Kounde, Wei Lin Sandra Sim, Oliver Simon, Gang Quan Wang, Hui Quan Yeo, Bryan KS Yeung, Fumiaki Yokokawa, Bin Zou
-
Patent number: 12012417Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.Type: GrantFiled: June 18, 2019Date of Patent: June 18, 2024Assignee: NOVARTIS AGInventors: Cyrille Kounde, Wei Lin Sandra Sim, Oliver Simon, Gang Wang, Hui Quan Yeo, Bryan K S Yeung, Fumiaki Yokokawa, Bin Zou
-
Patent number: 11597733Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.Type: GrantFiled: October 21, 2020Date of Patent: March 7, 2023Assignee: Novartis AGInventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, Jr., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
-
Publication number: 20220073535Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, A, L, m, n, p and q are as defined herein.Type: ApplicationFiled: June 18, 2019Publication date: March 10, 2022Inventors: Cyrille Kounde, Wei Lin Sandra Sim, Oliver Simon, Gang Wang, Hui Quan Yeo, Bryan KS Yeung, Fumiaki Yokokawa, Bin Zou
-
Publication number: 20210115065Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.Type: ApplicationFiled: October 21, 2020Publication date: April 22, 2021Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, JR., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
-
Patent number: 10428105Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.Type: GrantFiled: May 8, 2018Date of Patent: October 1, 2019Assignee: Novartis AGInventors: Martijn Fenaux, Oliver Saunders, Fumiaki Yokokawa, Weidong Zhong
-
Publication number: 20180258129Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Martijn FENAUX, Oliver SAUNDERS, Fumiaki YOKOKAWA, Weidong ZHONG
-
Patent number: 9988416Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.Type: GrantFiled: March 21, 2017Date of Patent: June 5, 2018Assignee: Novartis AGInventors: Martijn Fenaux, Oliver Saunders, Fumiaki Yokokawa, Weidong Zhong
-
Patent number: 9814739Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: GrantFiled: December 14, 2016Date of Patent: November 14, 2017Assignee: Novartis AGInventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
-
Publication number: 20170275329Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.Type: ApplicationFiled: March 21, 2017Publication date: September 28, 2017Inventors: Martijn FENAUX, Oliver SAUNDERS, Fumiaki YOKOKAWA, Weidong ZHONG
-
Publication number: 20170112868Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: ApplicationFiled: December 14, 2016Publication date: April 27, 2017Inventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
-
Patent number: 9556216Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are as defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: GrantFiled: August 27, 2013Date of Patent: January 31, 2017Assignee: Novartis AGInventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
-
Publication number: 20160289259Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: ApplicationFiled: June 16, 2016Publication date: October 6, 2016Applicant: Novartis AGInventor: Fumiaki Yokokawa
-
Publication number: 20150232501Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are as defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: ApplicationFiled: August 27, 2013Publication date: August 20, 2015Applicant: Novartis AGInventors: Sampath-Kumar ANADAN, Virender Singh AULAKH, Martijn FENAUX, Xiaodong LIN, Liang MAO, Oliver SAUNDERS, Zachary Kevin SWEENEY, Fumiaki YOKOKAWA, Weidong ZHONG
-
Publication number: 20140205566Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: wherein R1, R2 and R3 are as defined herein.Type: ApplicationFiled: November 21, 2013Publication date: July 24, 2014Applicant: NOVARTIS AGInventors: Lv LIAO, Fumiaki YOKOKAWA, Gang WANG
-
Publication number: 20140065101Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: ApplicationFiled: August 27, 2013Publication date: March 6, 2014Applicant: Novartis AGInventor: Fumiaki Yokokawa
-
Patent number: 8497286Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: GrantFiled: September 14, 2012Date of Patent: July 30, 2013Assignee: Novartis AGInventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Patent number: 8383650Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: GrantFiled: June 25, 2008Date of Patent: February 26, 2013Assignee: Novartis AGInventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Publication number: 20130005770Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.Type: ApplicationFiled: September 14, 2012Publication date: January 3, 2013Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
-
Patent number: 8178559Abstract: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.Type: GrantFiled: July 6, 2011Date of Patent: May 15, 2012Assignee: Novartis AGInventors: Werner Breitenstein, Takeru Ehara, Claus Ehrhardt, Philipp Grosche, Yuko Hitomi, Yuki Iwaki, Takanori Kanazawa, Kazuhide Konishi, Juergen Klaus Maibaum, Keiichi Masuya, Atsuko Iwasaki, Nils Ostermann, Masaki Suzuki, Atsushi Toyao, Fumiaki Yokokawa